Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia · Delayed Price · Currency is AUD 0.3050
-0.0100 (-3.17%)
Jan 30, 2026, 3:59 PM AEST
ASX:PAR Revenue
Paradigm Biopharmaceuticals had revenue of -16.70K AUD in the half year ending June 30, 2025.
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
136.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 79.22K | 58.67K | 285.52% |
| Jun 30, 2021 | 20.55K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Recce Pharmaceuticals | 7.51M |
| Starpharma Holdings | 5.85M |
| Actinogen Medical | 5.49M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |